Ebrantil, ampoules 5mg/ml 10ml, 5pcs

Composition

>

1 ml. contains urapidil hydrochloride 5.47 mg (which corresponds to 5.0 mg of urapidil),

Auxiliary substances:

propylene glycol;

sodium hydrophosphate dihydrate;

sodium dihydrophosphate dihydrate;

water for injection

Pharmacological action

Ebrantil is a drug that blocks postsynaptic alpha-1 adrenergic receptors, which reduces peripheral resistance. In addition, Ebrantil regulates the central mechanism of maintaining vascular tone and has a weak beta-adrenoblocking effect.

The heart rate (HR) and cardiac output do not change when it is administered. Low cardiac output can be increased by reducing vascular resistance. Orthostatic phenomena, as a rule, Ebrantil does not cause. Ebrantil blocks vasoconstriction caused by alpha-2-adrenergic receptors and does not cause reflex tachycardia due to vasodilation.

Ebrantil reduces systolic and diastolic blood pressure (BP) in a balanced way, reducing peripheral resistance and does not cause reflex tachycardia.

 Urapidil reduces pre-and post-loading on the heart, increases the efficiency of heart contraction, thereby, in the absence of arrhythmia, the drug increases the reduced minute volume of the heart.

Indications

Hypertensive crisis and severe, refractory hypertension. Controlled arterial hypotension during and after surgery.

Use during pregnancy and lactation

Contraindicated.

Contraindications

With caution: elderly, impaired liver and/or kidney function, hypovolemia. Hypersensitivity to the drug, open Botall duct; aortic stenosis, age up to 18 years, pregnancy, lactation (efficacy and safety have not been established).

Side effects

Most PE is caused by a sharp decrease in blood pressure.

Frequency: very often-more than 1/10; often-more than 1/100 and less than 1/10; infrequently-more than 1/1000 and less than 1/100; rarely-more than 1/10000 and less than 1/1000; very rarely-less than 1/10000, including individual reports.

From the cardiovascular system: infrequently-palpitations, tachycardia, bradycardia, feeling of compression behind the sternum, shortness of breath, arrhythmias.

From the digestive system: often-nausea, infrequently-vomiting.

From the central nervous system: often – dizziness, headache, fatigue; very rarely-anxiety.

From the skin: infrequently-increased sweating.

Allergic reactions: rarely-itching of the skin, redness of the skin, exanthema.

From the genitourinary system: often-proteinuria; rarely-nephropathy, nephrotic syndrome; rarely-priapism.

Laboratory parameters: very rarely – thrombocytopenia.

Interaction

The antihypertensive effect of urapidil may be enhanced when co-administered with alpha-blockers or other antihypertensive agents, as well as with hypovolemia (nausea, vomiting) and when taking ethanol.

With simultaneous use of cimetidine, the maximum concentration of urapidil in blood plasma can increase by 15%.

How to take, course of use and dosage

Ebrantil is administered intravenously in a jet stream or by prolonged infusion – lying down

Hypertensive crisis, severe arterial hypertension, refractory hypertension.

1) Intravenous: 10-50 mg of Ebrantil is slowly administered intravenously under the control of blood pressure (BP)/A decrease in blood pressure is expected within 5 minutes after use. Depending on the therapeutic effect, repeated use of Ebrantil is possible.

2) Intravenous drip or continuous infusion using a perfusion pump.

Maintenance dose: an average of 9 mg / h, i. e. 250 mg of Ebrantil (10 ampoules of 5 ml or 5 ampoules of 10 ml) in 500 ml of infusion solution (1 mg = 44 drops ~ 2.2 ml).

The maximum allowable ratio is 4 mg of Ebrantil per 1 ml of infusion solution.

Recommended maximum initial speed: 2 mg / min,

The rate of drip use depends on the patient’s blood pressure.

A solution for drip infusion, designed to maintain blood pressure, is prepared as follows: :

Usually 250 mg of the drug (10 ampoules of 5 ml or 5 ampoules of 10 ml) Ebrantil is added to 500 ml of an infusion solution, for example, saline solution,5 or 10% dextrose (glucose) solution. If a perfusion pump is used to administer the maintenance dose, then 100 mg of the drug (4 ampoules of 5 ml or 2 ampoules of 10 ml) Ebrantil® is injected into the syringe of a perfusion pump and diluted to 50 ml with saline,5 or 10% dextrose (glucose) solution.

Overdose

Symptoms:  dizziness, orthostatic collapse, fatigue, lethargy.

Treatment:  if blood pressure drops sharply, it is necessary to lift the patient’s legs and start infusion therapy to increase the volume of circulating blood. If these measures are ineffective, you can start an infusion of vasoconstrictors, under the control of blood pressure. In very rare cases, intravenous use of catecholamines (0.5 – 1.0 mg of epinephrine (epinephrine) diluted in 10 ml of saline solution) is necessary.

Special instructions

Use in pediatrics There are no clinical data on the use of the drug in children under 18 years of age. It can be used simultaneously with other antihypertensive agents used.

Form of production

Solution for intravenous use

Storage conditions

Store at a temperature not exceeding 30°C. Keep out of reach of children.

Shelf life

2 years

Active ingredient

Urapidil

Conditions of release from pharmacies

By prescription

Dosage form

solution for infusions

Description

For adults as directed by your doctor

Indications

Hypertension